{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+medication+%2B+Placebo+CRT", "query": { "intervention": "Placebo medication + Placebo CRT" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+medication+%2B+Placebo+CRT&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T08:31:10.368Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05042102", "title": "Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Donepezil + Cognitive remediation therapy (CRT)", "type": "COMBINATION_PRODUCT" }, { "name": "Donepezil + Placebo CRT", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo medication + Cognitive remediation therapy (CRT)", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo medication + Placebo CRT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "VA Connecticut Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 160, "start_date": "2022-08-08", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 1, "location_summary": "West Haven, Connecticut", "locations": [ { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05042102" }, { "nct_id": "NCT03745222", "title": "A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Concurrent chemoradiotherapy (cCRT)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-05-22", "completion_date": "2019-06-26", "has_results": true, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 14, "location_summary": "Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745222" }, { "nct_id": "NCT06532279", "title": "Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Nasopharyngeal Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage 0 Hypopharyngeal Carcinoma AJCC v8", "Stage 0 Nasopharyngeal Carcinoma AJCC v8", "Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage I Hypopharyngeal Carcinoma AJCC v8", "Stage I Laryngeal Cancer AJCC v8", "Stage I Lip and Oral Cavity Cancer AJCC v8", "Stage I Nasopharyngeal Carcinoma AJCC v8", "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Hypopharyngeal Carcinoma AJCC v8", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Nasopharyngeal Carcinoma AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stomatitis" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "MnSOD Mimetic BMX-001", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2025-06-23", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 153, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06532279" }, { "nct_id": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)", "Gastroesophageal Junction Carcinoma (GEJC)", "Esophageal Adenocarcinoma (EAC)" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2020-02-28", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 19, "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210115" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 200, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" }, { "nct_id": "NCT03237325", "title": "DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Oral Cavity and Oropharynx", "Oral Mucositis" ], "interventions": [ { "name": "SGX942", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Soligenix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2017-12-04", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 32, "location_summary": "Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03237325" }, { "nct_id": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab 400 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab placebo (saline)", "type": "DRUG" }, { "name": "Olaparib 300 mg BID", "type": "DRUG" }, { "name": "Olaparib matching placebo", "type": "DRUG" }, { "name": "Etoposide 100 mg/m^2", "type": "DRUG" }, { "name": "Platinum, investigator's choice", "type": "DRUG" }, { "name": "Standard Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Prophylactic Cranial Irradiation (PCI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 672, "start_date": "2020-12-08", "completion_date": "2027-11-15", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 35, "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624204" }, { "nct_id": "NCT00237809", "title": "D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "D-serine", "type": "DRUG" }, { "name": "Cognitive Retraining (CRT)", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cognitive Retraining Placebo", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 104, "start_date": "2002-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2017-05-10", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 2, "location_summary": "New Haven, Connecticut • West Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00237809" }, { "nct_id": "NCT00424255", "title": "Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 688, "start_date": "2006-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-07-18", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 5, "location_summary": "Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424255" }, { "nct_id": "NCT02324335", "title": "Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Neoplasms", "Mucositis" ], "interventions": [ { "name": "Brilacidin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Innovation Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2014-08-14", "completion_date": "2017-11-22", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-10-01T08:31:10.368Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02324335" } ] }